Side-by-side · Research reference
N-Acetyl Epitalon AmidatevsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED12/45 cited
BPhase 2HUMAN-REVIEWED8/46 cited
N-Acetyl Epitalon Amidate
Bioregulator Tetrapeptide · Khavinson School
SQ · Variable protocols
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
N-Acetyl Epitalon Amidate
TB-500
Primary target
DNA promoter regions (telomerase, RNA polymerase II, retinal genes)
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003Khavinson 2004
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
—
Endogenous protein at baseline; supplementation amplifies
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
—
—
02Dosage Protocols
Parameter
N-Acetyl Epitalon Amidate
TB-500
Standard dose
No standardized human dosing in indexed literature
In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
Not specified in candidate papers
2× per week (loading); then 1× per week (maintenance)
Evidence basis
In vitro human cell cultureKhavinson 2004Khavinson 2003
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Cell culture protocol
Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004
Cells made 10 extra divisions (44 passages total vs 34 in control).
—
Duration
Chronic treatment in aging culture
Sustained effect through late passages.
4–8 weeks loading; longer maintenance for chronic injury
Modification stability
N-acetyl + C-amide caps enhance peptidase resistance
Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.
—
Lower / starter dose
—
1 mg per injection
Reconstitution
—
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
—
Evening or pre-rest preferred (anecdotal)
Half-life
—
~2 hours (estimated; tissue uptake longer)
04Side Effects & Safety
Parameter
N-Acetyl Epitalon Amidate
TB-500
Human safety data
Not available in indexed literature
Candidate papers describe in vitro and animal models only.
—
Theoretical telomerase risk
Telomerase activation in somatic cells raises theoretical oncogenic transformation concern
—
Injection site reaction
—
Mild erythema, transient pain
GI symptoms
—
Rare nausea (anecdotal)
Cancer risk
—
Theoretical via angiogenesis pathway
Lethargy / fatigue
—
Reported anecdotally during loading phase
Antibody formation
—
No data (no long-term human trials)
Pregnancy / OB
—
Avoid
Long-term safety
—
Unknown beyond Phase 2
Absolute Contraindications
N-Acetyl Epitalon Amidate
- ·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
N-Acetyl Epitalon Amidate
- ·Individuals with hereditary cancer syndromes or high genetic cancer risk
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
N-Acetyl Epitalon Amidate
TB-500
1. Route
Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Reconstitution
Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Storage
Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.
Evening or pre-sleep is most common anecdotal timing.
4. Clinical protocols
Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
—
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
N-Acetyl Epitalon Amidate
+ Thymalin
ModerateBoth are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.
- Epitalon
- Protocol not defined in indexed literature
- Thymalin
- Tissue-specific bioregulator · separate dosing
- Rationale
- Complementary transcriptional targets
- Primary benefit
- Dual-axis aging intervention: cellular senescence + immune restoration
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair